LeMaitre Vascular specializes in innovative vascular surgery solutions, with a focus on devices that enhance surgical procedures and patient outcomes. One of their flagship products is the LeMaitre Valvulotome, which has significantly transformed in situ bypass techniques, becoming a preferred choice among vascular surgeons. This device has been instrumental in saving over 180,000 legs in the past decade, demonstrating its effectiveness and reliability in clinical settings. The company also emphasizes its global reach, with devices utilized in over 90 countries and supported by a dedicated team of more than 140 sales representatives.

In addition to the Valvulotome, LeMaitre offers a range of advanced vascular products, including the Flexcel™ Carotid Shunt and the Omniflow™ II Biosynthetic Vascular Prosthesis. The Flexcel™ Carotid Shunt is designed to ensure safety and clinical performance during carotid artery procedures, while the Omniflow™ II serves as a biosynthetic vascular prosthesis that provides a reliable alternative for vascular reconstruction. These technologies reflect LeMaitre's commitment to improving surgical outcomes and enhancing the quality of care for patients undergoing vascular procedures.

United States

LeMaitre is a provider of devices, implants and services for the treatment of peripheral vascular disease, a condition that affects more than 200 million people worldwide. The Company develops, manufactures and markets disposable and implantable vascular devices to address the needs of its core customer, the vascular surgeon. The Company's diversified product portfolio consists of brand name devices used in arteries and veins outside of the heart. The company is listed on NASDAQ.

LeMaitre Vascular

Company Details